Join

Compare · AZN vs INCR

AZN vs INCR

Side-by-side comparison of AstraZeneca PLC (AZN) and Intercure Ltd. (INCR): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both AZN and INCR operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • AZN is the larger of the two at $546.72B, about 9613.8x INCR ($56.9M).
  • Over the past year, AZN is down 6.3% and INCR is down 29.8% - AZN leads by 23.5 points.
  • AZN has hit the wire 24 times in the past 4 weeks while INCR has been quiet.
  • AZN has more recent analyst coverage (25 ratings vs 1 for INCR).
PerformanceAZN-6.35%INCR+22.69%
2026-02-02+0.00%2026-06-03
MetricAZNINCR
Company
AstraZeneca PLC
Intercure Ltd.
Price
$176.33-0.62%
$1.13+6.60%
Market cap
$546.72B
$56.9M
1M return
-3.87%
+22.83%
1Y return
-6.35%
-29.81%
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NYSE
NASDAQ
IPO
2026
News (4w)
24
0
Recent ratings
25
1
AZN

AstraZeneca PLC

AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

INCR

Intercure Ltd.

InterCure Ltd, together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.